表皮生长因子受体（EGFR）突变型非小细胞肺癌的免疫治疗：穷途末路还是崭露头角？ - Suppr

Suppr

超能文献

Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?

作者信息

Ketpueak Thanika, Tan Daniel S W, Popat Sanjay

机构信息

Lung Unit, Royal Marsden Hospital, London, United Kingdom.

Division of Oncology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.

出版信息

J Clin Oncol. 2024 Dec;42(34):4003-4007. doi: 10.1200/JCO.24.00829. Epub 2024 Aug 26.

DOI:10.1200/JCO.24.00829

PMID:39186708

Abstract

摘要

相似文献

Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer: End of the Road or the First Chapter?表皮生长因子受体（EGFR）突变型非小细胞肺癌的免疫治疗：穷途末路还是崭露头角？

J Clin Oncol. 2024 Dec;42(34):4003-4007. doi: 10.1200/JCO.24.00829. Epub 2024 Aug 26.

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer.CDKN2A缺失增强了表皮生长因子受体（EGFR）突变型非小细胞肺癌免疫治疗的疗效。

Cancer Res. 2025 Feb 1;85(3):585-601. doi: 10.1158/0008-5472.CAN-24-1817.

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.单细胞转录组分析揭示了 EGFR 突变型肺腺癌中抑制性的肿瘤免疫微环境。

J Immunother Cancer. 2022 Jan;10(2). doi: 10.1136/jitc-2021-003534.

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects.表皮生长因子受体突变型晚期非小细胞肺癌的免疫治疗：现状、可能机制与应用前景。

Front Immunol. 2022 Jul 22;13:940288. doi: 10.3389/fimmu.2022.940288. eCollection 2022.

Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs.免疫治疗联合方案优于单药治疗用于 EGFR 突变型非小细胞肺癌对 EGFR-TKIs 的获得性耐药。

Thorac Cancer. 2020 Dec;11(12):3501-3509. doi: 10.1111/1759-7714.13689. Epub 2020 Oct 19.

Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance.基于免疫疗法作为表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌患者在EGFR酪氨酸激酶抑制剂（TKI）耐药后的一种有前景的治疗方法。

Expert Rev Anticancer Ther. 2023 Feb;23(2):187-198. doi: 10.1080/14737140.2023.2170879. Epub 2023 Jan 31.

Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.表皮生长因子受体（EGFR）突变的非小细胞肺癌患者的围手术期免疫治疗：意想不到的潜在益处。

Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189194. doi: 10.1016/j.bbcan.2024.189194. Epub 2024 Oct 14.

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.罕见 EGFR 突变型非小细胞肺癌患者的 PD-L1 表达和 T 细胞浸润与免疫治疗反应。

Lung Cancer. 2020 Apr;142:98-105. doi: 10.1016/j.lungcan.2020.02.010. Epub 2020 Feb 19.

Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer.后续治疗对转化为小细胞肺癌的表皮生长因子受体（EGFR）突变型非小细胞肺癌患者临床结局的影响

Lung Cancer (Auckl). 2025 Apr 12;16:25-37. doi: 10.2147/LCTT.S516527. eCollection 2025.

Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.针对 CD73 通路介导的 - 突变型非小细胞肺癌的免疫代谢靶向治疗：克服免疫耐药性的新希望。

Front Immunol. 2020 Jul 14;11:1479. doi: 10.3389/fimmu.2020.01479. eCollection 2020.

引用本文的文献

Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.埃博霉素合成类似物：一类新型转录选择性抑制剂，可在难治性恶性胸膜间皮瘤中引发免疫原性细胞死亡。

J Exp Clin Cancer Res. 2024 Dec 21;43(1):327. doi: 10.1186/s13046-024-03253-y.

Patient, Caregiver, and Clinician Perspectives on the Time Burdens of Cancer Care.患者、照护者和临床医生对癌症护理时间负担的看法。

JAMA Netw Open. 2024 Nov 4;7(11):e2447649. doi: 10.1001/jamanetworkopen.2024.47649.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验